Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

LD2 is an inhibitor of protein arginine methyltransferase 9 (PRMT9; IC50 = 0.9 µM).1 It reduces the proliferation of Rec-1 and Raji lymphoblasts, UPN1 mantle cell lymphoma, BL-41 Burkitt lymphoma, and OCI-Ly3 diffuse large B cell lymphoma (DLBCL) cells (IC50s = 2.5-5 µM). LD2 (2.5 µM) induces cell cycle arrest at the G2/M phase in THP-1 acute myeloid leukemia (AML) cells. It decreases phosphorylated levels of checkpoint kinase 1 (Chk1) and Chk2 in THP-1 cells. In vivo, LD2 (10 mg/kg twice per day), in combination with an anti-programmed cell death protein 1 (anti-PD-1) antibody, decreases tumor volume in an AML mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Protein arginine methyltransferase 9 inhibitors and methods of use. AS 2024/0132887 Al, (2024).